VolitionRX (NYSEAMERICAN:VNRX – Get Free Report) will likely be announcing its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $0.71 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.
VolitionRX (NYSEAMERICAN:VNRX – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The medical research company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.41 million.
VolitionRX Trading Up 5.2%
NYSEAMERICAN:VNRX opened at $0.20 on Thursday. The company has a fifty day moving average of $0.26 and a 200-day moving average of $2.12. VolitionRX has a twelve month low of $0.16 and a twelve month high of $9.50.
Analysts Set New Price Targets
Separately, Benchmark reissued a “hold” rating on shares of VolitionRX in a research note on Monday, August 17th. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, VolitionRX has a consensus rating of “Hold” and a consensus price target of $28.00.
Check Out Our Latest Report on VNRX
About VolitionRX
VolitionRx Limited is a biotechnology company developing blood-based diagnostic tests intended to support the early detection and management of disease. Its technology platform, Nu.Q, analyzes nucleosomes—small structures released into the bloodstream when cells die—to identify biological signals associated with cancer and other conditions.
The company’s products and development programs serve human and veterinary health markets. Its Nu.Q Vet platform is designed to help veterinarians screen for and monitor cancer in companion animals, while the company is also developing Nu.Q-based applications for human cancer, infectious diseases, and other medical conditions.
Featured Stories
- Five stocks we like better than VolitionRX
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.
